/
LCTX
$1.35+$0.07 (+5.47%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$319.1M
249M shares
52-week range
$0.85 – $2.09
40% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
XASE
CS
Borrow rate
0.68%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-1.50
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $1.5M | $773.0K | $3.9M | $14.7M | $8.9M | $9.5M | $14.6M |
| Cost of revenue | $302.0K | $412.0K | $385.0K | $1.4M | $728.0K | $671.0K | $334.0K | $845.0K |
| Gross profit | $1.1M | $1.1M | $388.0K | $2.5M | $14.0M | $8.3M | $9.2M | $13.7M |
| Gross margin | 78.7% | 72.1% | 50.2% | 63.4% | 95.0% | 92.5% | 96.5% | 94.2% |
| R&D | $21.0M | $17.9M | $12.3M | $33.9M | $14.0M | $15.7M | $12.5M | $17.7M |
| Operating income | −$41.8M | −$38.9M | −$26.4M | −$49.2M | −$22.5M | −$24.7M | −$21.5M | −$21.8M |
| EBITDA | −$37.7M | −$35.9M | −$24.4M | −$42.4M | −$25.1M | −$22.6M | −$18.0M | −$67.9M |
| Net income | −$46.0M | −$11.7M | −$20.6M | −$43.0M | −$26.3M | −$21.5M | −$18.6M | −$63.5M |
| Net margin | -3247.9% | -792.2% | -2671.3% | -1104.2% | -178.7% | -240.2% | -195.9% | -436.5% |
| EPS (diluted) | -0.36 | -0.08 | -0.14 | -0.26 | -0.15 | -0.12 | -0.09 | -0.28 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $16M | $-0.07 | $-0.11–$-0.05 | 5 |
| 2027 | $10M | $-0.09 | $-0.20–$0.07 | 5 |
| 2028 | $46M | $0.01 | $-0.16–$0.61 | 5 |
| 2029 | $124M | $0.22 | $0.01–$0.50 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
www.lineagecell.com- Employees
- 77
- IPO / List date
- Mar 5, 1992
- HQ
- CARLSBAD, CA
Held by traders on TradeandTell
No one on the platform currently holds LCTX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,125,100 | $3.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded LCTX yet.
